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Abstract
Understanding how beneficial mutations affect fitness is crucial to our understanding of adaptation by natural selection.
Here, using adaptation to the antibiotic rifampicin in the opportunistic pathogen Pseudomonas aeruginosa as a model
system, we investigate the underlying distribution of fitness effects of beneficial mutations on which natural selection acts.
Consistent with theory, the effects of beneficial mutations are exponentially distributed where the fitness of the wild type is
moderate to high. However, when the fitness of the wild type is low, the data no longer follow an exponential distribution,
because many beneficial mutations have large effects on fitness. There is no existing population genetic theory to explain
this bias towards mutations of large effects, but it can be readily explained by the underlying biochemistry of rifampicin–
RNA polymerase interactions. These results demonstrate the limitations of current population genetic theory for predicting
adaptation to severe sources of stress, such as antibiotics, and they highlight the utility of integrating statistical and
biophysical approaches to adaptation.
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Introduction
Adaptation by natural selection ultimately depends on the
spread of novel beneficial mutations that increase fitness. Can we
predict the fitness effects of beneficial mutations? Gillespie[1,2]
argued that extreme value theory (EVT) provides a simple answer
to this question: the tails of all-Gumbel type distributions (a very
flexible type of distribution that includes many familiar distribu-
tions, including the normal) are exponential. As such, the fitness
effects of beneficial mutations will be exponentially distributed
provided that the fitness of the wild-type is high enough so that
beneficial mutations are drawn from the extreme tail of the
distribution of fitness effects of mutations. It is however unclear
how robust this theory is with respect to the fitness of the
population prior to selection. As the absolute fitness of the wild-
type decreases (for example, because of environmental change), a
larger proportion of single mutations will increase fitness.
Beneficial mutations will therefore no longer be drawn exclusively
from the tail of the distribution, hence the exponential distribution
may no longer apply (Figure 1).
In this paper, we investigate how the distribution of fitness
effects of beneficial mutations changes with the fitness of the
wildtype population using the evolution of antibiotic resistance in
the opportunistic pathogen Pseudomonas aeruginosa as a model
system. Experimental studies of the underlying distribution of
fitness effects of beneficial mutations[3,4,5,6] have lagged behind
the theory, both because beneficial mutations are exceedingly rare
and because beneficial mutations of small effect are less likely to
reach appreciable frequencies in populations because of the
combined effects of drift[7] and competition between independent
mutations[8]. To overcome these limitations, we used a fluctuation
test to isolate clones of the bacterium Pseudomonas aeruginosa with
mutations in the b-subunit of RNA polymerase (rpoB) that are
beneficial in the presence of the drug rifampicin [9,10,11]. Our
experimental design ensured that we obtained an unbiased sample
of all beneficial mutations. First, we isolated mutants from
populations that were propagated in culture media lacking
rifampicin, implying that we isolated beneficial mutations prior
to any selection for rifampicin resistance. Second, we experimen-
tally prevented competition (ie clonal interference[8]) among
independently derived beneficial mutations by randomly choosing
independent mutants. Third, we ensured all mutations included in
the analyses were unique by sequencing rpoB of the mutants. To
test the hypothesis that the fitness effects of beneficial mutations
are exponentially distributed, we used log-likelihood tests that have
been specifically developed to test this hypothesis using this
experimental design[12].
Using this approach, we show that the distribution of fitness
effects of beneficial mutations is variable: under conditions where
the fitness of the wild-type is high, the fitness effects of beneficial
mutations are exponentially distributed, as predicted by theory.
However, when the fitness of the wildtype is low, the data may no
longer fit an exponential distribution because many beneficial
mutations have large effects on fitness. We show that this non-
exponential distribution of fitness effects emerges as a direct
consequence of the molecular interactions that are under selection
in this system and we argue that existing theory on the fitness
effects of beneficial mutations cannot be applied to understand
adaptation to novel stressful environments, such as those provided
by antibiotics.
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To investigate how the distribution of fitness effects of beneficial
mutations changes with the fitness of the wild-type, we measured
the fitness of beneficial mutations isolated at a high concentration
of rifampicin (Table 1) and the wild-type across a gradient of
rifampicin concentrations (Figure 2). At low concentrations of
rifampicin (1–2 ug/mL), the fitness of the wildtype is high and we
cannot reject the null hypothesis that the fitness effects of beneficial
mutations are exponentially distributed, as determined by a
likelihood-ratio test (Figure 3, Table 2). However, at high
concentrations of rifampicin (.2 ug/mL), the fitness of the wild-
type is low and the fitness effects of beneficial mutations are not
exponentially distributed (Figure 3, Table 2).
One limitation of this study is that our power to test the null
hypothesis is weakest under conditions where the fitness of the wild-
type is high, because only half of the mutants that we isolated
increase fitness at low concentrations of rifampicin. Given that we
had to sample 80 mutants in order to identify 15 beneficial
mutations (this saturation effect is in part attributable to a strong
mutational bias towards two mutations), it unlikely that increasing
the sample size of our study would have substantially increased the
power of our analysis. It is also important to note that this limitation
is not unique to this study: beneficial mutations are rare events, and
all other comparable experimental evolution studies are based on a
similar sample size of beneficial mutations[4,13].
To gain insight into the mechanistic basis of fitness, we measured
both the growth rate in the absence of antibiotics and the degree of
rifampicin resistance for each beneficial mutation (Figure 4). At low
concentrations of rifampicin (ie 1–2 ug/mL), selection for high
levels of resistance is weak, and fitness is highly correlated with
growth rate in the absence of antibiotics (r=.86–.9, P,.0001). The
genetic variation in growth rate in the absence of antibiotics
generated by spontaneous mutation is normally distributed
(Figure 3; W=.92, P=.21), hence the fitness effects of beneficial
mutations are exponentially distributed because only mutations in
the right tail of the distribution (ie those mutations that are
associated with a low cost of resistance[14]) are beneficial at low
concentrations of rifampicin. At high concentrations of rifampicin,
selection for resistance is strong and the fitness effects of beneficial
mutations no longer fit an exponential distribution because most
beneficial mutations had large effects on resistance and, therefore,
fitness at high concentrations of rifampicin (Figure 4).
The large effect of beneficial mutations on resistance is consistent
with the molecular interactions that occur between rifampicin and
RNA polymerase. Structural studies have shown that rifampicin
binds to a small, highly conserved pocket of the b-subunit of RNAP
and only 12 amino acid residues are involved in direct interactions
Figure 1. A schematic of the distribution of fitness effects of
beneficial mutations. This figure is a schematic showing how the
distribution of fitness effects of beneficial mutations can change
depending on the absolute fitness of the wild type (shown with vertical
lines) in two different arbitrary distributions of mutational effects on
fitness. Note that the distribution of fitness effects of beneficial
mutations is very similar in both of these distributions when the fitness
of the wild-type is high (short dashed line).
doi:10.1371/journal.pgen.1000406.g001
Author Summary
Adaptation by natural selection depends on the spread of
novel beneficial mutations, and one of the most important
challenges in our understanding of adaptation is to be
able to predict how beneficial mutations impact fitness.
Here, we investigate the underlying distribution of fitness
effects of beneficial mutations that natural selection acts
on during the evolution of antibiotic resistance in the
opportunistic human pathogen P. aeruginosa. When the
fitness of the wild type is high, most beneficial mutations
have small effects. This finding is consistent with existing
population genetic models of adaptation based on
statistical theory. When the fitness of the wild type is
low, most beneficial mutations have large effects. This
distribution cannot be explained by population genetic
theory, but it can be readily understood by considering the
biochemical basis of resistance. This study confirms an
important prediction of population genetic theory, and it
highlights the need to integrate statistical and biochemical
approaches to adaptation in order to understand evolu-
tion in stressful environments, such as those provided by
antibiotics.
Table 1. Beneficial mutations.
Mutation in rpoB Amino acid change
1552CGC1553 +P518 (insertion between 517 and 518)
A1553G Q518R
A1553T Q518L
A1562G D521G
A1562T D521V
A1592G H531R
A1592T H531L
A455G Q152R
A455T Q152L
C1550T S517L
C1552A Q518K
C1563G D521E
C1591T H531Y
C1607T S536F
C1706T P569L
This table shows the beneficial mutations in rpoB that we identified in this
study. We used a fluctuation test to isolate a total of 80 independent clones
carrying beneficial mutations and sequencing revealed that each one of the
clones carried one of 15 non-synonymous mutations in rpoB. We used one
representative clone carrying each of these beneficial mutations in our
experiments.
doi:10.1371/journal.pgen.1000406.t001
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PLoS Genetics | www.plosgenetics.org 2 March 2009 | Volume 5 | Issue 3 | e1000406Figure 2. Fitness effects of beneficial mutations. Plotted points show the fitness, r, of the wild-type (open symbol) and beneficial mutations
(filled symbols) at different concentrations of rifampicin. Fitness was estimated as the mean growth rate of 12 to 18 cultures of each strain at each
concentration of rifampicin (standard errors not shown).
doi:10.1371/journal.pgen.1000406.g002
Figure 3. Distribution of fitness effects of beneficial mutations. Plotted points show wi,j, the difference in fitness between beneficial
mutations (i.e. those mutations that give higher fitness than the ancestral clone) and the least-fit beneficial mutation at each concentration of
rifampicin. P values show the probability that the observed distribution of fitness effects of beneficial mutations is exponential (see table 2 for further
statistical details).
doi:10.1371/journal.pgen.1000406.g003
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increase in resistance (mean IC50=423 ug/mL, s.e=25 ug/mL,
n=10). Residues that surround the binding pocket interact only
indirectly with rifampicin, and it has been argued that resistance
arises at these residues due to amino acid changes that alter the
folding of the protein in the binding pocket. We identified only a
small number of beneficial mutations (n=4) in residues that are
involved in indirect Rif-RNAP interactions and mutations at these
residuesgiverisetointermediatelevelsofrifampicinresistance(mean
IC50=197 ug/mL, s.e=40 ug/mL, n=4). This biophysical ap-
proach to understanding the effects of beneficial mutations suggests
thatthedata maynolongerfit an exponentialdistribution because of
the high specificity of interactions between rifampicin and RNA
polymerase: changes to the majority of amino acids that are involved
in rifampicin-RNAP interactions results in large increases in
resistance and, therefore, large increases in fitness at high
concentrations of rifampicin. To test this hypothesis further, we
assayed fitness in the presence of sorangicin[15], an antibiotic that
has been shown to bind to the same domain of RNAP as rifampicin
and share the same mode of action, inhibition of transcription
initiation[16]. The biochemical difference between these antibiotics
comes from the fact that sorangicin has a much higher conforma-
tional flexibility than rifampicin [16]. The fitness consequence of this
difference is that many mutations that give a large increase in fitness
under high concentrations of rifampicin give only a small increase in
fitness in the presence of an equivalent dose of sorangicin (Figure 4),
and the observed distribution of fitness effects of beneficial mutations
does not differ significantly from the exponential (Figure 5,
22logL=5.72, n=9, P=.09).
It is important to note that these results do not necessarily imply
that the distribution of fitness effects of mutations that are
beneficial in the presence of sorangicin is universally exponential.
Most mutations that increase sorangicin resistance do so by
altering membrane permeability, instead of altering the structure
of RNAP[16], but unfortunately the mutations that are responsible
for this decrease in permeability to sorangicin are not known and
we are therefore unable to measure the underlying distribution of
fitness effects of mutations that are beneficial in the presence of
sorangicin. Instead, our interpretation of this result is that it
provides a clear demonstration that the high-affinity interactions
that occur between rifampicin and RNAP are ultimately
responsible for the non-exponential distribution of fitness effects
of beneficial mutations at high concentrations of rifampicin.
Conclusion
The variability in the distribution of fitness effects of beneficial
mutations in this study is consistent with population genetic
theory. When the fitness of the wild-type is high, beneficial
mutations can be viewed from a statistical perspective as
Table 2. Testing the exponential distribution.
[Rifampicin] mg/L
Relative growth rate
of wild type (rPAO1,j) 22logL nP
1 .79 3.47 9 .265
2 .70 2.4 9 .361
8 .38 7.62 14 .039
64 .001 10.71 15 .0086
We used a likelihood ratio test to test the null hypothesis that the fitness effects
of beneficial mutations are exponentially distributed at different concentrations
of rifampicin (see methods for details). n gives the number of mutations that
increase fitness at each dose of antibiotic. The growth rate of the wild-type
strain was standardized relative to the growth rate of this clone in antibiotic-
free medium.
doi:10.1371/journal.pgen.1000406.t002
Figure 4. Phenotypic traits under selection. Plotted points show the rifampicin resistance and growth rate in media lacking rifampicin of
beneficial mutation (filled symbols) and the wildtype (open symbols).
doi:10.1371/journal.pgen.1000406.g004
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fitness effects of mutations, hence the fitness effects of beneficial
mutations will be exponentially distributed. However, EVT does
not specify how high fitness has to be in order for this theory to
apply. In our experimental system, this distribution held over a
wide range of parameter space: we failed to detect significant
deviations from the exponential distribution when the fitness of the
wild-type was reduced by 20–30%. When the fitness of the wild-
type is low, statistical theory does not make any predictions
regarding the form of the distribution of fitness effects of beneficial
mutations and hence there is no reason to expect an exponential
distribution. Comparable experimental studies in viral systems are
in agreement with this idea: Sanjuan and colleagues [4] found that
the fitness effects of beneficial mutations are exponentially
distributed in VSV under conditions where the fitness of the
wild-type is high, while Rokyta et al. [3] found that the fitness
effects of beneficial mutations that allow phage to attack novel
hosts (ie hosts that are inaccessible to a WT virus) are not
exponentially distributed. Note that in these and our experiments,
the data may stop fitting the exponential distribution under
conditions of low wildtype fitness not only because EVT, by
definition, no longer applies, but also because the underlying
mutational distributions may vary with environmental conditions.
Despite our lack of certainty of the statistical explanation for the
observed distribution when the fitness of the wild-type is low, we
have a good molecular mechanistic explanation (in retrospect we
may have been able to predict this distribution a priori).
Specifically, the distribution is biased towards mutations of large
effect as a result of the high specificity of interactions between
rifampicin and RNA polymerase that arises from the low
conformational flexibility of rifampicin. Antibacterial and antiviral
drugs are usually involved in highly specific interactions with their
target proteins [17], suggesting that a bias towards mutations of
large effect may be a general feature of adaptation to antibiotics
[17,18] and other situations when high-specificity protein-ligand
interactions are under strong selection, for example during host-
parasite interactions[19] or when enzymes are selected to
recognize novel substrates[20,21].
Recently, there has been considerable interest among popula-
tion geneticists in developing general models of adaptation based
on the statistical properties of extreme events. Our work highlights
both the strengths and limitations of this approach and we suggest
that the development of a complete theory of adaptation will
require integrating molecular biology, in order to be able to
predict the impact of mutations on fitness, and statistical
approaches to adaptation, to be able to understand how natural
selection samples the distribution of fitness effects of beneficial
mutations during adaptive walks.
Materials and Methods
Isolation of Beneficial Mutations
A single clone of Pseudomonas aeruginosa PAO1 was inoculated
into 5 ml of M9KB medium that was incubated overnight at 37 C
with constant shaking (150 rpm). This overnight culture was
diluted down 10
26 into fresh M9KB and 120 uL aliquots of this
diluted culture were used to setup 480 cultures on 5 96 well
microplates. These cultures were incubated overnight at 37 C
without shaking. To isolate beneficial mutations, 5 uL of each of
the 480 overnight cultures was plated out on M9KB supplemented
with 62.11 ug/mL of rifampicin, the minimal concentration
required for complete inhibition of growth of the wildtype strain.
Figure 5. Fitness in the presence of sorangicin. This figure shows the fitness of beneficial mutations (filled symbols) and the ancestral clone
(open symbol) at 64 mg/L rifampicin (n=18 replicates/genotype) and 20 mg/L sorangicin (n=6 replicates/genotype). The dashed line is a plot of
y=x.
doi:10.1371/journal.pgen.1000406.g005
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each of the first 80 cultures that gave samples containing exactly 1
colony on agar plate containing rifampicin.
Sequencing
To determine the mutations underlying adaptation, we
sequenced the rpoB gene in each of the 80 colonies that we
isolated in our fluctuation test. Genomic DNA was isolated from
each colony using a Wizard Genomic DNA extraction kit
(Promega, UK) as per the manufacturer’s instructions. Our
sequencing strategy was to first sequence a highly-conserved
domain of rpoB that is known to be important for rifampicin
resistance in all 80 clones. This region was amplified with primers
rpoB_fwd (59-GTTCTTCAGCGCCGAGCG-39) and rpoB_rev
(59-GCGATGACGTGGTCGGC-39) that amplify the region of
the rpoB gene between nucleotides 1178 and 1864. Reaction
mixtures consisted of BIOTAQ polymerase (Bioline, UK), 1 mM
dNTPs, 16 nM (NH4)2SO4, 62.5 mM Tris-HCL (pH 8.8), .01%
Tween 20, 2 mM MgCl2, and each primer at a concentration of
.2pM. Amplification reactions were carried out as follows: 94 C
for 5 minutes, followed by 35 cycles of 94 C for 30 seconds, 60 C
for 30 seconds, and 72 C for 1 minute, followed by a final
incubation at 72 C for 10 minutes. PCR products were purified
using a MultiScreen PCR96 filter plate (Millipore, UK) as per the
manufacturer’s instructions. Purified PCR products were se-
quenced with both forward and reverse primers using BigDye
3.1 sequencing (Applied Biosystems International) followed by
ethanol/EDTA precipitation of sequencing products. In all cases,
this strategy identified either a single mutation in this region of
rpoB or no mutations.
Clones that lacked a mutation in the highly conserved domain of
rpoB were subsequently sequenced for a second region that has
previously been implicated in rifampicin resistance spanning
nucleotides 1 to 1012 of the rpoB gene. This region was amplified
and sequenced with primers rpoB_up (59–ATGGCTTACTCATA-
CACTGAG-39) and rpo_B1 (59-CTCGATGCG CACGACCTG
-39). The protocol was the same as described above, except that the
annealing temperature used in the PCR reactions was 54 C instead
of 60 C. We idenfied a single mutation in this region in all of the
clones that did not contain a mutation in the highly conserved
domain of rpoB. As a further control, we sequenced the entire rpoB
gene in six randomly chosen clones. We failed to detect any second
site mutations in rpoB using this approach.
Fitness Assay
To assay fitness, we estimated the growth rate, r, of each
beneficial mutation and wildtype PAO1 at 4 different concentra-
tions of rifampicin (0,1,2,8, and 64 mg/L). Pre-assay overnight
cultures of each mutant were prepared by growth in M9KB. These
cultures were then diluted 100 fold into fresh culture medium and
we measured the growth rate of each culture using an automated
microplate reader by taking hourly measurements of optical
density at 600 nm (OD600) over a period of approximately
12 hours. All incubations were carried out at 37 C. Assays at
low concentrations of rifampicin (0,1,2,8 mg/L) were carried out
with 12 fold replication and assays at high concentrations of
rifampicin (64 mg/L) were carried out with 18 fold replication. A
further assay was carried out using the same method to measure
fitness in the presence of sorangicin (20 ug/mL). OD600 is
proportional to the log of cell density, and the slope of OD600
against time (mOD/min) in exponential growth phase therefore
provides an estimate of r, the growth rate of the bacterial clone,
such that ri,j is the growth rate to the i
th genotype at the j
th
concentration of rifampicin.
Statistical Analysis
To test the hypothesis that the fitness effects of beneficial
mutations are exponentially distributed, we used a likelihood ratio
test developed by Beisel and colleagues [12]. According to EVT,
there are three limiting tail distributions, the Fre ´chet (which has a
heavier-than-exponential tail), the Gumbel (which has an
exponential tail), and the Weibull (right-truncated). The tails of
all three of EVT domains can be described by the generalized
Pareto distribution (GPD), which has a cumulative distribution
function given by:
Fx k,t j ðÞ ~
1{ 1z kx
t
   {1=k, x§0, if kw0 Frechet ðÞ
1{ 1z kx
t
   {1=k,0 ƒxv{ t
k,i fkv0 Weibull ðÞ
1{e{x=t, x§0, if k~0 Gumbel ðÞ
8
> > <
> > :
9
> > =
> > ;
with shape parameter k and scale parameter t. One very
interesting property of the GPD is that the shape parameter is
threshold-independent. This property of the GPD is critical,
because it implies that it is possible to account for any potential
bias against detecting mutations of small beneficial effect by simply
re-scaling fitness data so that the fitness of beneficial mutations is
expressed relative to the least-fit beneficial mutation instead of the
wild-type. To take advantage of this property, we estimated the
fitness of each beneficial mutation as as wi,j=ri,j2r1,j where wi,j is
the fitness of the i
th beneficial mutation in the j
th environment, ri,j is
the growth rate of the i
th beneficial mutation in the j
th
environment, and r1,j is the growth rate of the least fit beneficial
mutation in the the j
th environment (ie the beneficial mutation that
has the smallest increase in growth rate relative to the rifampicin
sensitive clone in the j
th environment).
The likelihood ratio test developed by Beisel and colleagues
calculates 22logL, negative twice the difference in log-likelihood
between two statistical models, one model in which the shape
parameter of the GPD is set to 0 and the other in which the scale
parameter of the GPD is free to vary (ie H0:k=0, H A: k?0). P
values were calculated by performing 10000 parametric bootstrap
replicates using a software package (EVDA) developed for R
(software available at http://www.webpages.uidaho.edu/,joyce/
Lab%20Page/Computer-Programs.html). This test is potentially
sensitive to measurement error, but the accuracy of our fitness
measurements was high enough (Average CV=19.8%) that
measurement error should not inflate the probability of making
a type I error [12].
Inhibition Assays of rpoB Mutants
To measure the resistance conferred by rpoB mutations, we
assayed growth in media containing rifampicin at different
concentrations. Pre-assay cultures of rpoB mutants and PAO1 were
prepared by overnight growth of freezer cultures in M9KB at 37 C.
These cultures were then diluted 2.5610
25 into M9KB, or M9KB
supplemented with rifampicin at the following concentrations (all in
ug/mL): 0,3.9,7.8,15.6, 31.3,62.5,125, 250,500, and 1000.Assay
cultures were incubated at 37 C and we measured the optical
density of cultures after exactly 24 hours of incubation (+/
210 minutes) at 600 nM using an automated microplate reader.
We assayed the resistance of 12 cultures of each of the rpoB mutants
that we identified and 12 replicates of PAO1. Resistance was
calculated as IC50, the concentration of rifampicin necessary to
cause a 50% reduction in optical density, using the following
regression model: y~yminzymax{ymax
.
1z10 log IC50{x ðÞ   H
  
,
where y is optical density, measured in absorbance units, x is the
Beneficial Mutations in Pseudomonas aeruginosa
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parameter that estimates the rate of decay in optical density with
increasing rifampicin concentration.
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